The American Cancer Society (ACS) has issued a major update to its prostate cancer screening recommendations, encouraging more men to receive regular blood tests to detect the disease earlier. The new guidance, released on November 12, 2026, recommends prostate-specific antigen (PSA) screening every two years for men at average risk between the ages of 50 and 69.
The recommendation represents a significant change from the organization’s previous approach, which emphasized shared decision-making between patients and healthcare providers rather than directly recommending regular screening for all eligible men.
The updated guidelines also call for earlier and more frequent screening among certain higher-risk groups. Black men and men with a strong family history of prostate cancer should generally begin annual testing at age 45.
The change comes as researchers report stronger evidence that PSA screening can reduce deaths from prostate cancer. At the same time, medical experts continue to warn about false-positive results, unnecessary biopsies and treatment of cancers that might never become life-threatening.
What the New Prostate Cancer Screening Guidelines Recommend
The updated ACS guidelines establish different screening schedules depending on a man’s age and risk factors.
For men at average risk, the organization recommends a PSA blood test every two years from ages 50 through 69. This recommendation applies to men who do not have a first-degree family history of prostate cancer, do not have known or suspected inherited genetic mutations associated with increased risk, and do not identify as Black.
For higher-risk groups, screening should begin earlier.
The recommendations include:
- Average-risk men: PSA screening every two years from ages 50 through 69.
- Black men: Annual PSA screening from ages 45 through 69.
- Men with a strong family history: Annual screening from ages 45 through 69 when a first-degree relative was diagnosed before age 65 or multiple first-degree relatives have had prostate cancer.
- Men with one first-degree relative diagnosed at age 65 or older: PSA screening every two years from ages 45 through 69.
- Men ages 70–74: Individualized decisions based on health, personal preferences and the balance of benefits and risks.
- Men ages 75 and older: Routine screening is not recommended by the ACS.
These recommendations are based on the organization’s updated evidence review and modeling research. They are intended to identify potentially dangerous cancers earlier while reducing unnecessary medical procedures.
Why Black Men and Men With Family History Should Start Earlier
The ACS identifies Black men and men with certain family histories as groups with increased prostate cancer risk.
Black men in the United States experience higher rates of prostate cancer and prostate cancer deaths than the overall male population. The updated guidance therefore recommends beginning annual PSA testing at age 45 rather than waiting until age 50.
Family history also matters. A man whose father, brother or son developed prostate cancer before age 65 may face a higher risk than someone without that history.
The ACS also recommends annual screening for men with multiple first-degree relatives diagnosed with the disease, regardless of their ages at diagnosis.
However, a man with only one first-degree relative diagnosed at age 65 or older falls into a different screening category. The recommendation for this group is testing every two years from ages 45 through 69.
These distinctions show why age alone should not determine when someone begins screening. Family medical history and other risk factors can influence the recommended schedule.
What Is a PSA Blood Test?
A prostate-specific antigen test measures the amount of PSA in a man’s blood. PSA is a protein produced by cells in the prostate gland.
Doctors use PSA levels to help identify men who may need additional evaluation for prostate cancer. The test involves taking a blood sample, which is then analyzed in a laboratory.
However, an elevated PSA level does not automatically mean a person has cancer. Prostate enlargement, inflammation and other conditions can also increase PSA levels.
A normal PSA result also cannot guarantee that cancer is absent. The test is a screening tool, not a definitive diagnosis.
The ACS recommends repeating certain elevated PSA results before moving to more invasive testing. This approach can help reduce unnecessary procedures caused by a single abnormal result.
Why the American Cancer Society Changed Its Earlier Guidance
The previous ACS guideline, published in 2010, did not directly recommend routine PSA screening for all men in eligible age groups. Instead, it emphasized discussions between patients and healthcare providers about the potential benefits and harms.
The November 2026 update reflects changes in the evidence available to medical researchers.
According to the ACS, stronger evidence now indicates that PSA-based screening can reduce prostate cancer deaths and lower the likelihood of detecting the disease only after it has reached an advanced stage.
The organization also points to improvements in how doctors evaluate abnormal PSA results and manage cancers that appear unlikely to become dangerous.
These developments include greater use of magnetic resonance imaging (MRI), additional biomarker tests and active surveillance for selected low-risk cancers.
The ACS concluded that these strategies can help reduce some of the harms historically associated with prostate cancer screening.
Why Prostate Cancer Screening Has Remained Controversial
Prostate cancer screening has been debated for years because detecting more cancers does not always mean improving patients’ health or extending their lives.
Many prostate cancers grow slowly. Some may never cause symptoms or threaten a person’s life, particularly when diagnosed in older men with other health conditions.
Screening can identify these slow-growing cancers, potentially leading to additional tests, biopsies and treatment that patients might not need.
Treatment can also cause serious side effects, including urinary incontinence, erectile dysfunction and bowel problems.
False-positive PSA results create another concern. A man may receive an elevated result even though he does not have prostate cancer. This can lead to anxiety and additional medical procedures.
The updated ACS guideline attempts to balance these risks against evidence that regular screening can help identify aggressive cancers earlier.
The organization recommends that healthcare providers explain the potential benefits, limitations and harms before patients begin screening.
What Happens After an Elevated PSA Result?
An elevated PSA result does not automatically lead to a prostate biopsy.
The updated ACS guideline recommends repeating the test before considering further evaluation in men whose PSA levels reach specified thresholds.
For men ages 45 through 69, a PSA level of 3.0 ng/mL or higher should prompt repeat testing. For men ages 70 through 74, the threshold is 6.5 ng/mL or higher.
The repeat test should preferably take place between two weeks and three months after the initial result.
If the PSA remains elevated, healthcare providers should offer additional evaluation, including MRI and/or a validated biomarker test, to help determine whether a biopsy is necessary.
These steps are designed to make the diagnostic process more careful and reduce the chance of unnecessary biopsies.
How the New Guidance Compares With Earlier U.S. Recommendations
The ACS update does not mean every major medical organization now recommends the same screening schedule.
The U.S. Preventive Services Task Force (USPSTF), in its existing recommendation, says men ages 55 through 69 should make an individual decision about PSA screening after discussing the potential benefits and harms with a healthcare professional. It recommends against routine screening for men aged 70 and older.
The USPSTF guidance dates from 2018, while the ACS published its updated recommendation in November 2026.
The difference highlights the continuing debate over how widely PSA screening should be offered and how clinicians should balance early detection against potential overtreatment.
Patients should therefore understand which guideline their healthcare provider follows and discuss how their personal risk factors affect screening decisions.
What Men Should Know Before Scheduling Screening
The updated recommendation provides clearer screening intervals, but it does not mean every man should automatically undergo testing without a medical discussion.
Men approaching age 50 can discuss the new recommendation with their healthcare providers. Those who are Black or have a strong family history may need to consider screening earlier, beginning at age 45.
Men ages 70 through 74 should make individualized decisions based on their overall health, preferences and expected benefits. The ACS does not recommend routine screening for men aged 75 and older, and screening is also not recommended for men who are not expected to live another 10 years.
The central message is that early detection can matter, but screening decisions should reflect individual circumstances.
Frequently Asked Questions About Prostate Cancer Screening
1. At what age should men start prostate cancer screening?
Under the 2026 ACS guidelines, average-risk men should begin PSA screening at age 50. Black men and men with certain strong family histories should generally begin at age 45.
2. How often should men get a PSA blood test?
Average-risk men ages 50–69 should get tested every two years. Black men and men with a strong family history should generally receive annual testing from ages 45–69.
3. Does a high PSA level mean prostate cancer?
No. An elevated PSA level can result from prostate cancer or other conditions, including prostate enlargement and inflammation. Doctors may repeat the test and recommend additional evaluation before making a diagnosis.
4. Should men over 70 continue prostate cancer screening?
The ACS recommends individualized decision-making for men ages 70–74. It does not recommend routine screening for men aged 75 and older.
5. What are the risks of prostate cancer screening?
Potential harms include false-positive results, unnecessary biopsies, overdiagnosis and treatment side effects. These may include urinary problems, erectile dysfunction and bowel complications.
6. Is the PSA test the same as a prostate cancer diagnosis?
No. PSA is a screening blood test. A high result may lead to further evaluation, but it does not independently confirm cancer.
7. Why did the American Cancer Society change its screening guidance?
The ACS cited stronger evidence that PSA screening can reduce prostate cancer deaths and advanced-stage diagnoses, along with improved methods for evaluating abnormal results and managing low-risk cancers.
A Major Change in Prostate Cancer Early Detection
The American Cancer Society’s November 2026 update marks a significant shift toward regular prostate cancer screening for men at average and increased risk. By recommending biennial testing for average-risk men and earlier screening for higher-risk groups, the organization aims to improve early detection while limiting unnecessary procedures.
The new guidance does not eliminate the controversy surrounding PSA testing. Instead, it reflects evolving evidence and improved diagnostic approaches. Men should discuss their age, family history, health and screening preferences with a qualified healthcare professional before deciding on testing.
SEO Title: Prostate Cancer Screening 2026: New ACS Guidelines Recommend PSA Testing
Meta Description: New 2026 prostate cancer screening guidelines recommend PSA blood tests every two years for average-risk men and earlier annual screening for higher-risk groups.
Focus Keyword: prostate cancer screening
Related Keywords: prostate cancer screening guidelines 2026, PSA blood test, American Cancer Society screening, prostate cancer early detection, prostate cancer risk factors, PSA testing age.
Long-Tail Keywords:
- New prostate cancer screening recommendations for men
- At what age should men get prostate cancer screening?
- How often should men get a PSA blood test?
- Prostate cancer screening guidelines for Black men
- Prostate cancer screening for men with family history
- American Cancer Society PSA screening recommendations 2026
URL Slug: prostate-cancer-screening-new-acs-guidelines-2026
Category: Health News
Image SEO
- Image Title: New Prostate Cancer Screening Guidelines 2026
- Image Alt Text: Healthcare professional collecting a blood sample for a prostate-specific antigen PSA screening test
- Image Caption: The American Cancer Society now recommends regular PSA blood testing for average-risk men ages 50 to 69.
- Image Description: A healthcare professional performs a blood draw representing the PSA blood test used in prostate cancer screening, following the American Cancer Society’s updated 2026 recommendations.
Tags: Prostate Cancer, Prostate Cancer Screening, PSA Test, American Cancer Society, Cancer Screening Guidelines, Men’s Health, Health News, Early Cancer Detection